FDA announces new safety labeling for GLP-1 RA medications

Feed excerpt — reported by UPI

The FDA announced new safety labeling for GLP-1 RA medications such as Ozempic, warning of a potential increased risk for a rare eye condition.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at UPI →

View MAP Context →